Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World CongressGlobeNewsWire • 04/23/25
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee OsteoarthritisGlobeNewsWire • 04/21/25
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ OsteoarthritisGlobeNewsWire • 04/03/25
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with OsteoarthritisGlobeNewsWire • 03/17/25
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee OsteoarthritisGlobeNewsWire • 03/04/25
Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee OsteoarthritisGlobeNewsWire • 03/03/25
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 01/10/25
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ OsteoarthritisGlobeNewsWire • 12/11/24
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee OsteoarthritisGlobeNewsWire • 12/05/24
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3Accesswire • 11/26/24
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic ArthritisGlobeNewsWire • 11/14/24
Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 10/31/24
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with OsteoarthritisGlobeNewsWire • 10/30/24
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee OsteoarthritisGlobeNewsWire • 09/24/24
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to BuyZacks Investment Research • 09/11/24
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 08/30/24
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 07/19/24
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee OsteoarthritisGlobeNewsWire • 06/17/24
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisGlobeNewsWire • 04/16/24
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with SepsisGlobeNewsWire • 04/11/24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With SepsisGlobeNewsWire • 04/11/24